Humacyte, Inc. Stock-Based Compensation
Humacyte, Inc. (HUMA) reported Stock-Based Compensation of $5.78 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-12
- Humacyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.61M, a 11.69% increase year-over-year.
- Humacyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $3.17M, a 27.46% increase year-over-year.
- Humacyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.47M, a 45.81% increase year-over-year.
- Humacyte, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.46M, a 58.57% increase year-over-year.
- Humacyte, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $9.75M, a 58.92% increase from fiscal 2024.
- Humacyte, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $6.14M, a 10.12% decline from fiscal 2023.
- Humacyte, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $6.83M, a 10.41% increase from fiscal 2022.
- Humacyte, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $6.18M, a 39.05% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $5.78M 10-Q · filed 2026-08-12 | $8.25M derived: sum of 3 quarters · filed 2026-08-12 | $10.71M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $3.17M 10-Q · filed 2026-05-13 | $5.64M derived: sum of 2 quarters · filed 2026-05-13 | $8.10M derived: sum of 3 quarters · filed 2026-05-13 | $10.44M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $4.93M derived: sum of 2 quarters · filed 2026-03-27 | $7.27M derived: sum of 3 quarters · filed 2026-08-12 | $9.75M 10-K · filed 2026-03-27 |
| 2025-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.80M derived: sum of 2 quarters · filed 2026-08-12 | $7.28M 10-Q · filed 2025-11-12 | $8.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.82M 10-Q · filed 2026-08-12 | $6.52M derived: sum of 3 quarters · filed 2026-08-12 | $8.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.49M 10-Q · filed 2026-05-13 | $4.18M derived: sum of 2 quarters · filed 2026-05-13 | $5.73M derived: sum of 3 quarters · filed 2026-05-13 | $7.17M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $3.25M derived: sum of 2 quarters · filed 2026-03-27 | $4.68M derived: sum of 3 quarters · filed 2026-03-27 | $6.14M 10-K · filed 2026-03-27 |
| 2024-09-30 | $1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.99M derived: sum of 2 quarters · filed 2025-11-12 | $4.44M 10-Q · filed 2025-11-12 | $5.85M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $2.89M 10-Q · filed 2025-08-11 | $4.30M derived: sum of 3 quarters · filed 2025-08-11 | $6.07M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.45M 10-Q · filed 2025-05-13 | $2.86M derived: sum of 2 quarters · filed 2025-05-13 | $4.63M derived: sum of 3 quarters · filed 2025-05-13 | $6.47M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $3.18M derived: sum of 2 quarters · filed 2025-03-31 | $5.02M derived: sum of 3 quarters · filed 2025-03-31 | $6.83M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $3.61M derived: sum of 2 quarters · filed 2024-11-08 | $5.42M 10-Q · filed 2024-11-08 | $7.09M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $3.65M 10-Q · filed 2024-08-13 | $5.32M derived: sum of 3 quarters · filed 2024-08-13 | $6.80M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $1.81M 10-Q · filed 2024-05-13 | $3.48M derived: sum of 2 quarters · filed 2024-05-13 | $4.96M derived: sum of 3 quarters · filed 2024-05-13 | $6.45M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $1.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $3.15M derived: sum of 2 quarters · filed 2024-03-28 | $4.64M derived: sum of 3 quarters · filed 2024-03-28 | $6.18M 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.97M derived: sum of 2 quarters · filed 2023-11-09 | $4.51M 10-Q · filed 2023-11-09 | $7.33M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $3.04M 10-Q · filed 2023-08-14 | $5.85M derived: sum of 3 quarters · filed 2023-08-14 | $7.73M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.55M 10-Q · filed 2023-05-12 | $4.36M derived: sum of 2 quarters · filed 2023-05-12 | $6.24M derived: sum of 3 quarters · filed 2023-05-12 | $9.16M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $4.69M derived: sum of 2 quarters · filed 2023-03-24 | $7.62M derived: sum of 3 quarters · filed 2023-03-24 | $10.15M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.81M derived: sum of 2 quarters · filed 2022-11-10 | $7.33M 10-Q · filed 2022-11-10 | $8.56M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $5.46M 10-Q · filed 2022-08-12 | $6.69M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $2.53M 10-Q · filed 2022-05-13 | $3.76M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $4.69M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $3.47M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |